Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study

Published:2016-10-11 Issue:1 Volume:24 Page:22-27
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Tapper E. B.¹,Bacon B. R.²,Curry M. P.¹,Dieterich D. T.³,Flamm S. L.⁴,Guest L. E.⁵,Kowdley K. V.⁶,Lee Y.⁵,Tsai N. C.⁷,Younossi Z. M.⁸,Afdhal N. H.¹

Affiliation:

1. Division of Gastroenterology/Hepatology; Department of Medicine; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA

2. Division of Gastroenterology/Hepatology; Saint Louis University School of Medicine; Saint Louis MO USA

3. Division of Liver Diseases; Department of Medicine; Mount Sinai School of Medicine; New York NY USA

4. Division of Hepatology; Northwestern University Feinberg School of Medicine; Chicago IL USA

5. Trio Health Analytics; La Jolla CA USA

6. Liver Care Network; Swedish Medical Center; Seattle WA USA

7. The Liver Center; Queen's Medical Center; Honolulu HI USA

8. Center for Liver Diseases; Department of Medicine; Inova Fairfax Hospital; Falls Church VA USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12611/fullpdf

Reference22 articles.

1. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

2. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014

3. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease;Charlton;Gastroenterology,2015

4. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study;Curry;Gastroenterology,2015

5. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation;Forns;Hepatology,2015

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated‐Test‐stage Treat study final outcomes;Journal of Viral Hepatitis;2023-11-28

2. A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China;The Lancet Regional Health - Western Pacific;2023-07

3. Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients;Liver International;2023-03-08

4. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients;World Journal of Gastroenterology;2022-12-07

5. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts;Journal of General Internal Medicine;2022-04-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3